Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476242 · ClinicalTrials.gov registry record · Phase 2
Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT00476242 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 82 participants.
The verdict
NCT00476242, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
Prospective participants will undergo a screening process at the clinic to determine eligibility. After screening, eligible patients will complete an 8-day inpatient detoxification, followed by a 12-week outpatient phase. Patients will be randomly assigned to one of two conditions (1) Naltrexone + Placebo; (2) Naltrexone + Memantine 20 mg bid. Long-acting, injectable form of naltrexone (Vivitrol) will be administered once per month (the total of three injections) while memantine or placebo will be taken daily. In addition, patients will receive twice weekly psychosocial intervention that will include motivational interviewing and cognitive-behavioral relapse prevention. The outpatient treatment will also consist of 3 weekly visits to the clinic in which patients will receive counseling to help maintain abstinence and improve compliance with study medication.
Interventions
- DRUG memantine
- DRUG Vivitrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00476242
The ClinicalTrials.gov registry entry for NCT00476242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which memantine is the first listed.
NCT00476242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00476242 about?
NCT00476242 is a clinical study titled "Memantine as a Supplement to Naltrexone in Treating Heroin Dependence". Prospective participants will undergo a screening process at the clinic to determine eligibility. After screening, eligible patients will complete an 8-day inpatient detoxification, followed by a 12-week outpatient phase. Patients will be randomly assigned to one of two conditions (1) Naltrexone + P...
What is the current status of trial NCT00476242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2008-06. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00476242?
The interventions under investigation include: memantine (DRUG), Vivitrol (DRUG).
Who is sponsoring clinical trial NCT00476242?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.